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Infections with Shiga toxin (Stx)-producing bacteria cause bloody diarrhea which may progress to life-
threatening complications, including acute renal failure and neurological abnormalities. The precise mecha-
nism of disease progression is unclear, although evidence suggests that the localized production of the host
proinflammatory cytokines tumor necrosis factor alpha (TNF-a) and interleukin-1 may exacerbate toxin-
mediated vascular damage. Purified Stxs have been demonstrated to elicit proinflammatory cytokine synthesis
from human peripheral blood mononuclear cells and monocytic cell lines in vitro. To understand toxin-
monocyte interactions required for cytokine synthesis, we have treated differentiated THP-1 cells with purified
wild-type toxins, enzymatic mutants, or B subunits and measured TNF-a production. Our data suggest that A
subunit enzymatic activity is essential for cytokine production. THP-1 cells were treated with a series of protein
kinase C (PKC), PKA, and protein tyrosine kinase inhibitors to examine the role of intracellular signaling
molecules in Stx-mediated cytokine production. Treatment of cells with PKC and tyrosine kinase inhibitors
blocked TNF-a secretion by Stx-stimulated THP-1 cells. Stx treatment directly activated PKC, which occurred
at a point upstream of transcriptional activation of the gene encoding TNF-a.
Shiga toxins (Stxs) are a group of antigenically and function-
ally related protein toxins produced by the enteric pathogens
Shigella dysenteriae serotype 1 and Escherichia coli serotypes
categorized as enterohemorrhagic E. coli. All members of the
Stx family are AB5 holotoxins composed of an approximately
32-kDa A subunit protein in noncovalent association with a
pentameric ring of identical B subunit proteins, each with a
molecular mass of ;7.7 kDa. The A subunit is the enzymatic
component of the toxins and acts as a highly specific N-glyco-
sidase enzyme hydrolyzing the bond between ribose and a
single adenine residue found on a prominent loop structure in
the 28S rRNA component of eukaryotic ribosomes (6, 30). The
depurination reaction results in the rapid inhibition of protein
synthesis. Toxin binding to cells is mediated by B subunits
which primarily associate with the membrane neutral glycolip-
ids globotriaosylceramide (Gb3; Gala134Galb134GlcCer)
(16, 18) and globotetraosylceramide (Gb4; GalNAcb13
3Gala134Galb134GlcCer) (4, 29). S. dysenteriae serotype 1
produces the prototypical Stx, whereas E. coli has been shown
to elaborate one or more toxins closely related to Stx, desig-
nated Stx1, Stx2, Stx2c, Stx2d, and Stx2e (reviewed in reference
22).
Although infections with Stx-producing organisms generally
cause self-limited bloody diarrhea, patients are at increased
risk for the development of life-threatening complications.
Chief among these complications are progression to acute re-
nal failure (hemolytic uremic syndrome) and neurological ab-
normalities, such as seizures, stroke, and coma (17, 34). A
frequent pathologic finding in these sequelae is damage to
capillaries in the colon, kidneys, and central nervous system
(12). Thus, Stxs appear to selectively damage microvascular
endothelial cells. This concept was supported by work demon-
strating that human vascular endothelial cells were killed when
exposed to purified Stx in vitro (23). It was subsequently shown
that human endothelial cells were sensitized to the cytotoxic
action of Stxs by treatment of the cells with the proinflamma-
tory cytokines tumor necrosis factor alpha (TNF-a) or inter-
leukin 1 (IL-1) (19, 38, 42). The mechanism of sensitization
involved increased endothelial cell Gb3 biosynthesis through
TNF receptor p55 signaling and protein kinase C (PKC) acti-
vation (20, 41). Thus, the proinflammatory cytokine response
to Stxs may contribute to pathogenesis by sensitizing endothe-
lial cells to the direct toxic effects of Stxs.
Cellular sources of proinflammatory cytokines produced in
vivo in response to Stxs remain to be characterized. However,
it has been shown that human monocytes and monocytic cell
lines respond to the toxins by synthesizing and secreting
TNF-a, IL-1b, and IL-6 (26, 43). Using Northern blot analyses,
we showed that Stxs affect cytokine expression, at least in part,
at the transcriptional level via mechanisms that may involve
activation of the DNA-binding proteins nuclear factor kB (NF-
kB) and activator protein-1 (28). The precise mechanisms by
which Stxs, potent protein synthesis inhibitors that interact
with membrane glycolipids, transduce signals in monocytes
necessary to activate cytokine gene expression are not known.
The experiments reported here are designed to elucidate the
toxin components necessary for proinflammatory cytokine in-
duction and to initially characterize host cell signaling path-
ways involved in cytokine expression.
MATERIALS AND METHODS
Toxins and cytokine inducers. Purified Stx1 and Stx2e were prepared from
recombinant E. coli strains expressing toxin operons under control of thermoin-
ducible promoters. Toxins were purified from bacterial sonicates by sequential
DEAE-Sepharose and chromatofocusing column chromatography or MonoQ
high-performance liquid chromatography as previously described (10, 29, 38). At
each step, fractions were tested for Vero cell cytotoxicity by using the assay of
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Gentry and Dalrymple (8). A purified Stx1 enzymatic mutant, in which glutamate
at position 167 and arginine at position 170 in the A subunit were replaced with
glutamine and leucine, respectively (Stx1-E167Q-R170L), by oligonucleotide-
directed site-specific mutagenesis, was the kind gift of Yoshifumi Takeda, Na-
tional Institute of Infectious Diseases, Tokyo, Japan. The preparation and pu-
rification of Stx1-E167Q-R170L has been described previously (24). The mutant
Stx1 holotoxin exhibited high-performance liquid chromatography and sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) profiles similar
to those of the wild-type toxin. Ouchterlony double gel diffusion with antisera
raised against the mutant toxin showed a line of identity between Stx1-E167Q-
R170L and wild-type Stx1, and both toxin preparations were shown to bind Gb3
by thin-layer chromatography (24, 45). A purified Stx2e enzymatic mutant in
which glutamate at position 167 was replaced with glutamine (Stx2e-E167Q) was
the kind gift of James E. Samuel, Texas A&M University Health Science Center,
College Station, Tex. Stx2e-E167Q mutagenesis and purification procedures
have been published (10). The E167Q-R170L and E167Q point mutations re-
duce verocytotoxicity approximately 105- to 106-fold compared to the verocyto-
toxicities of wild-type Stx1 and Stx2e, respectively (10, 24). Purified pentameric
Stx1 B subunits were the kind gift of David Acheson, Tufts University School of
Medicine (Boston, Mass.). Molecular biology and purification procedures for the
Stx1 B subunit preparation have been reported (1). Endotoxin contamination of
all toxin preparations was tested by Limulus amoebocyte lysate assay (Pyrotell,
Associates of Cape Cod, Inc., Falmouth, Mass.) prior to use in cytokine induc-
tion experiments. Ricin and purified E. coli O111:B4 lipopolysaccharide (LPS)
were purchased from Sigma Chemical Co., St. Louis, Mo. Murine monoclonal
immunoglobulin M antibody pK002 directed against Gb3 was purchased from
Accurate Chemical Corp. (Westbury, N.Y.).
Cells. The human myelogenous leukemia cell line THP-1 (40) was purchased
from American Type Culture Collection (Manassas, Va.) and maintained in
RPMI 1640 (Gibco BRL, Grand Island, N.Y.) supplemented with penicillin (50
U/ml), streptomycin (50 mg/ml), and 10% fetal bovine serum (FBS; Hyclone
Laboratories, Logan, Utah). Vero cells were grown in Minimum Essential Me-
dium (Gibco BRL) with Earle’s salts, 10 mM L-glutamine, and the supplements
listed above. L929 cells were cultured in Iscove’s modified Dulbecco’s medium
with 10% FBS. All cells were maintained at 37°C in humidified 5% CO2.
Macrophage differentiation. THP-1 cells (106 cells/ml) grown in 60-mm-diam-
eter culture dishes were induced to differentiate to a mature macrophage-like
state by treatment with phorbol-12-myristate-13-acetate (PMA; Sigma) at 50
ng/ml for 48 h. Plastic-adherent, differentiated cells were then washed twice in
cold Dulbecco’s phosphate-buffered saline (PBS) and incubated with fresh me-
dium lacking PMA for 72 h with daily medium changes prior to use in experi-
ments. Unless otherwise noted, differentiated THP-1 cells were used in all ex-
periments.
Analysis of protein synthesis. Stx enzymatic activity was examined by measur-
ing the inhibition of [3H]leucine incorporation into nascent polypeptides. Briefly,
THP-1 or Vero cells grown in 24-well microtiter plates were incubated with
purified Stxs (400 ng/ml) for various time points. At each time point, toxins were
removed from the cells by three washes with cold sterile PBS. Forty microliters
of labeling medium containing 10 mCi of [3H]leucine (DuPont New England
Nuclear, Boston, Mass.) in leucine-free RPMI 1640 plus 10% FBS was added to
each well, and the cells were incubated for 30 min at 37°C. The plates were then
placed on ice, and excess radiolabel was removed by washing with cold PBS.
Twenty microliters of RIPA buffer (0.15 M Tris-HCl [pH 7.4], 0.5% sodium
deoxycholate, 0.5% NP-40, and 0.1% SDS) was added to each well. Lysates were
transferred to microcentrifuge tubes. An additional 20 ml of RIPA buffer was
added to the wells to collect any residual lysates. Lysates were centrifuged at
12,700 3 g for 15 min at 4°C. Resultant supernatants were transferred to What-
man GF/C filter papers and allowed to dry. Filters were treated twice with 10%
trichloroacetic acid and once with 100% ethanol and were allowed to air dry.
Filters were placed in scintillant, and radioactivity was measured using a scintil-
lation counter (Beckman LS8000; Beckman Instruments Inc., Fullerton, Calif.).
Analysis of TNF-a expression. Amounts of immunoreactive TNF-a in culture
supernatants were measured by enzyme-linked immunosorbent assay (Quan-
tikine, R&D Systems, Minneapolis, Minn.) according to the manufacturer’s
instructions. The sensitivity of the assay is 4.4 pg/ml. TNF bioactivity in culture
supernatants was measured by the lysis of actinomycin D-treated L929 cells as
previously described (37). We have previously shown that purified toxins at 400
to 800 ng/ml induce optimal signals in these assays.
Kinase inhibitors. PKC inhibitors H-7 and K252a, PKA inhibitor H-89, and
protein tyrosine kinase inhibitor genistein were purchased from Calbiochem, La
Jolla, Calif. H-7 and H-89 were dissolved in sterile water and stored at 4°C.
K252a was dissolved in dimethyl sulfoxide (DMSO)-ethanol (50:50 [vol/vol]) at
500 mg/ml. Genistein was dissolved in DMSO at 500 mg/ml. K252a and genistein
were stored at 220°C before use. Differentiated THP-1 cells were treated with
the indicated concentrations of inhibitors for 2 h (genistein) or 3 h (H-7, H-89,
and K252a). The cells were then washed twice in cold PBS and treated with the
inhibitors in the presence or absence of Stx1, LPS, PMA, or vehicle control.
Trypan blue exclusion studies showed no loss of cell viability in response to
treatment of the cells with inhibitors alone. For all experiments, the percentage
of organic solvents did not exceed 0.2% and had no effect on TNF-a expression.
Determination of PKC activity. THP-1 cells were treated with Stx1 in the
presence or absence of kinase inhibitors. The cells were washed twice in cold PBS
and pelleted by centrifugation at 100 3 g for 5 min at 4°C. Cells were resus-
pended in 50 mM Tris-HCl (pH 7.5) containing 0.3% (wt/vol) b-mercaptoetha-
nol, 1.0 mM EDTA, 2.5 mM EGTA, 50 mg of phenylmethylsulfonyl fluoride per
ml, and 10 mM benzamidine. The cells were disrupted by sonication, and the
homogenates were cleared by centrifugation at 135,000 3 g for 45 min. Total
cellular PKC activity in sonicates was examined by measuring the phosphoryla-
tion of a synthetic PKC-specific substrate in the presence of a [g-32P]ATP donor
(Biotrak PKC System; Amersham Corp., Arlington Heights, Ill.) per the manu-
facturer’s instructions. PKC activity (picomoles of phosphate transferred/minute/
106 cells) is expressed as a percentage of basal (untreated cells) levels.
Northern blot analysis of TNF-a mRNA. Total cellular RNA was extracted
from THP-1 cells by the acid guanidinium isothiocyanate method (2) using
Ultraspec II RNA isolation kits (Biotecx Laboratories, Houston, Tex.). RNA
purity was assessed by optical density readings at 260 and 280 nm. Ten micro-
grams of RNA per lane was subjected to electrophoresis using 0.8% agarose–2.0
M formaldehyde gels in 13 MOPS (morpholinepropanesulfonic acid) running
buffer at 50 V for 2 to 3 h. RNA was transferred to positively charged nylon
membranes (GeneScreen Plus; NEN DuPont, Boston, Mass.) by using a Tur-
boblotter Rapid Downward Transfer System (Schleicher and Schuell, Keene,
N.H.) and was cross-linked by exposing the membrane to UV light (254 nm) for
a total dose of 120 mJ/cm2 (UV Crosslinker; Bio-Rad, Hercules, Calif.). A
human TNF-a probe, 59-ATC TCT CAG CTC CAC GCC ATT GGC CAG
GAG-39 (Clontech, Palo Alto, Calif.), was 59-end labeled with [g-32P]ATP. An
18S RNA antisense control template (Ambion Inc., Austin, Tex.) was random
prime labeled using MegaPrime DNA labeling kits (Amersham). After labeling,
unincorporated nucleotides were removed using G-25 Sephadex columns. Mem-
branes were treated with 7 to 10 ml of Rapid-Hyb hybridization buffer (Amer-
sham) for 15 min at 42°C for the TNF-a probe or 65°C for the 18S RNA probe.
Approximately 106 cpm of TNF-a probe was added per milliliter of hybridization
buffer and hybridization was carried out at 42°C for 2 to 4 h. Membranes were
washed in 23 SSC–0.1% SDS for 10 min at room temperature and were exposed
to a phosphorimager screen overnight (13 SSC is 0.15 M NaCl plus 0.015 M
sodium citrate). The screen was analyzed by a phosphorimager (Molecular Dy-
namics, Sunnyvale, Calif.), and sums of counts above the background were
calculated using ImageQuant software (Molecular Dynamics). Membranes were
stripped by boiling in 0.13 SSC–0.1% SDS twice for 15 min and hybridized with
18S RNA probe at 65°C as an internal control for RNA loading. Ratios of counts
of TNF-a transcripts to 18S RNA were calculated. To minimize interassay
variability, relative levels of TNF-a mRNA from three separate experiments are
shown by expressing the ratios as percentages above basal (unstimulated) levels
by using the following formula:
(stimulated ratio of counts of TNF-a/18S RNA) 2 (unstimulated ratio of counts of TNF-a/18S RNA)
(unstimulated ratio of counts of TNF-a/18S RNA) 3 100
Phosphotyrosine analysis. Eighteen hours prior to stimulation, differentiated
THP-1 cells were serum starved in medium containing 0.5% FBS. The cells were
then exposed to 1.0 mM genistein or an equivalent volume of DMSO vehicle
control for 2 h prior to stimulation. The medium was replaced with medium
containing purified Stx1 (400 ng/ml) with or without the kinase inhibitor. Fol-
lowing 1 h of incubation at 37°C, cells were washed twice with cold PBS and lysed
with modified RIPA buffer (1.0% NP-40, 1.0% sodium deoxycholate, 150 nM
NaCl, 10 mM Tris-HCl [pH 7.5], 5.0 mM sodium pyrophosphate, 1.0 mM
NaVO4, 5.0 mM NaF, 1.0 mg of aprotinin/ml, 1.0 mg of leupeptin/ml, and 0.1 mM
phenylmethylsulfonyl fluoride) for 15 min at 4°C. DNA was sheared by passing
cell lysates through 22 1/2- and 26 3/8-gauge needles. Lysates were cleared by
centrifugation at 14,900 3 g for 15 min at 4°C. Protein content of cell lysates was
determined using the Micro BCA assay kit (Pierce, Rockford, Ill.). Equivalent
amounts of proteins were separated by SDS–12% PAGE and analyzed by West-
ern blotting using an anti-phosphotyrosine monoclonal antibody (4G10; UBI,
Lake Placid, N.Y.) and anti-mouse immunoglobulin G-horseradish peroxide
(HRP) as the secondary antibody. Blots were developed using the ECL system
(Amersham) by following the manufacturer’s instructions.
Statistics. Two sample-paired t tests were performed using Minitab Release 8
statistical software (Minitab, Inc., State College, Pa.).
RESULTS
Stx induction of TNF-a requires A subunit activity. Earlier
studies have shown that, in contrast to epithelial or endothelial
cells, human peripheral blood monocytes and differentiated
monocytic cell lines express low levels of membrane Gb3 and
are relatively resistant to the cytotoxic action of purified Stxs,
with 50% cytotoxic doses (CD50s) of .1.0 mg/ml (26). How-
ever, monocytic cells are not unresponsive to the toxins; they
respond by internalizing toxins and synthesizing the proinflam-
matory cytokines TNF-a, IL-1b, and IL-6 (26, 43). Our pre-
liminary studies showed that toxin receptor binding by purified
Stx1 B subunits did not elicit monocyte cytokine production.











We hypothesized, therefore, that enzymatically active Stx A
subunits may be necessary for cytokine induction. We exam-
ined this hypothesis by treating differentiated THP-1 mono-
cytic cells for 18 h with purified Stx holotoxins or Stx holotoxin
molecules containing point mutations in the A subunit catalytic
site (Stx1-E167Q-R170L, Stx2e-E167Q). The ability of Stxs to
induce TNF-a production appeared to require A subunit en-
zymatic activity (Table 1). To further link TNF-a production
with toxin enzymatic activity, THP-1 cells were treated with
sublethal or lethal concentrations of ricin (CD50, ;5.0 ng/ml),
the Ricinus communis toxic lectin that shares N-glycosidase
activity with Stx A subunits. Ricin treatment also elicited
TNF-a production. In contrast, reagents which bind to Gb3 in
the absence of enzymatic activity, i.e., purified Stx A subunit
mutants, purified Stx1 B subunits, or anti-Gb3 monoclonal
antibody, did not induce TNF-a synthesis.
To correlate ribosomal inactivation with cytokine produc-
tion, we examined protein synthesis inhibition in cells treated
with Stxs. When toxin-sensitive Vero cells (CD50 5 1.0 pg/ml)
were treated with purified Stx1 or Stx2e (400 ng/ml), the in-
corporation of 3[H]leucine into nascent polypeptides was in-
hibited by approximately 90% within 1 h of toxin treatment
(Fig. 1). We previously showed that undifferentiated THP-1
cells express relatively high levels of membrane Gb3, are sen-
sitive to Stx1 (CD50 5 18 pg/ml), and fail to produce TNF-a
when stimulated with Stxs (26). Within an hour of treatment
with purified Stx1 (400 ng/ml), undifferentiated THP-1 cells
manifested an approximate 75% reduction in protein synthesis.
In contrast, when differentiated THP-1 cells were treated with
an equivalent dose of Stx1, we noted transient increases in total
protein synthesis 1 to 2 h after toxin treatment. Following
treatment of cells with Stx2e, protein synthesis was inhibited
by, at most, 20% over a 4-h time period. Thus, the sublethal
amounts of Stxs used in these experiments to induce TNF-a
expression from differentiated monocytic cells only marginally
affected total protein synthesis.
Stx induction of TNF-a requires serine/threonine kinase
activity. Many studies have implicated serine/threonine kinases
of the PKC family as monocyte/macrophage signal transduc-
tion molecules required for cytokine production (reviewed in
reference 36). We hypothesized that PKC may also participate
in Stx-mediated cell signaling. A series of PKC inhibitors was
TABLE 1. TNF-a production by THP-1 cells requires Stx A
subunit enzymatic activity
Toxin treatment Receptor specificity TNF-a(pg/ml)a
Stx1 (800 ng/ml) Gb3 149.2 6 23.1
Stx1A2 (E167Q-R170L)
(400 ng/ml)








Gb3 45.0 6 1.1
c
Stx1 B subunits Gb3 12.9 6 2.7
Anti-Gb3 antibody Gb3 17.3 6 4.6
Stx2e (800 ng/ml) Gb4 275.2 6 34.2
Stx2eA2 (E167Q) Gb4 22.8 6 4.9
d
Ricin (0.33 ng/ml) Terminal galactose residues 66.2 6 16.3
Ricin (5.0 ng/ml) Terminal galactose residues 225.3 6 26.1
Ricin (10 ng/ml) Terminal galactose residues 222.4 6 27.5
LPS (200 ng/ml) Multiple receptors 1055 6 55
Media 51.0 6 10.8
a Data are expressed as means 6 standard errors of the mean. Results are
from at least three independent experiments for each treatment.
b P , 0.0001 for Stx1 versus Stx1A mutants.
c P , 0.0002 for Stx1 versus Stx1A mutants at 1 mg/ml.
d P , 0.0001 for Stx2e versus Stx2eA mutants.
FIG. 1. Protein synthesis inhibition mediated by purified Stxs. Differentiated THP-1 cells were treated with 400 ng of purified Stx 1 (h) or Stx2e (E) per ml, and
undifferentiated THP-1 cells ({) and Vero cells () were treated with 400 ng of Stx1/ml. At the indicated time points, cells were washed and incubated an additional
30 min in medium containing [3H]leucine. Following lysis of the cells and trichloroacetic acid precipitation of proteins, incorporation of radiolabeled leucine into
nascent polypeptides was measured by scintillation counting. The data are expressed as percentages of basal protein synthesis (untreated cells) and are derived from
at least three independent experiments.











employed to monitor the effects of blocking kinase activity on
TNF production by Stx1-treated THP-1 cells. Treatment of
cells with the PKC inhibitor H-7 (Fig. 2A) or K252a (Fig. 2B)
reduced TNF secretion in a dose-dependent manner following
stimulation of cells with Stx1 for 12 h. Although H-7 and K252a
are potent inhibitors of PKC, they can also inhibit cyclic nu-
cleotide-dependent protein kinases (14). To exclude the in-
volvement of PKA in Stx-induced TNF production, the PKA
inhibitor H-89 was used. H-89 inhibits PKA activity at nano-
molar concentrations, whereas the inhibitory concentration for
PKC is several hundredfold higher. Treatment of THP-1 cells
with concentrations of H-89 ranging from 0.1 to 1,000 nM did
not result in significant decreases in TNF production in re-
sponse to Stx1 (data not shown). These data suggest that mem-
bers of the PKC family of serine/threonine kinases are involved
in Stx signaling for cytokine production.
The capacity of Stx1 to activate PKC was directly assessed.
Total cellular PKC activity in lysates prepared from Stx1-
treated monocytes was examined by measuring the transfer of
the g-phosphate group from [g-32P]ATP to a PKC-specific
substrate. Treatment of THP-1 cells with Stx1 increased total
cellular PKC activity to ;150% above basal levels in untreated
cells (Fig. 3). Treatment of cells with H-7 or K252a prior to
Stx1 exposure prevented elevated PKC activity, whereas H-89
treatment did not affect Stx1-mediated PKC activity. Short-
term PMA treatment was used as a positive control and in-
creased THP-1 PKC activity by ;350%.
PKC inhibitors block TNF-a mRNA synthesis in Stx-treated
THP-1 cells. Northern blot analyses of Stx-treated THP-1 cells
demonstrated that the toxins act, at least in part, at the tran-
scriptional level to increase quantities of TNF-a mRNA tran-
scripts extracted from the cells (28). We used Northern blots to
examine the role of PKC in Stx-induced TNF-a mRNA syn-
thesis. Pretreatment of cells with the PKC inhibitors H-7 and
K252a significantly blocked TNF-a transcript induction follow-
ing stimulation with Stx1, while the PKA inhibitor H-89 did not
affect toxin induction of TNF-a mRNA (Fig. 4). These data
suggest PKC involvement in signaling events occurring up-
stream of TNF-a transcriptional activation. The positive con-
trol in these experiments, short-term treatment of THP-1 cells
with TPA, triggered TNF-a mRNA synthesis.
Stx induction of TNF-a requires tyrosine kinase activity.
One of the earliest macrophage responses to LPS binding is
the phosphorylation of multiple proteins at tyrosine residues
(reviewed in reference 3). Treatment of THP-1 cells with pu-
rified Stxs also results in tyrosine phosphorylation (and de-
phosphorylation) of multiple proteins. Following toxin stimu-
lation, major phosphoprotein bands at approximately 73, 70,
60, and 20 kDa appeared, while a 33-kDa band appeared
dephosphorylated (Fig. 5). Toxin-mediated changes in phos-
phorylation appeared to be sensitive to the general tyrosine
FIG. 2. Effect of PKC inhibitors on Stx1-mediated TNF production by
THP-1 cells. PMA-differentiated THP-1 cells were pretreated with various doses
of the PKC inhibitors H-7 (A) or K252a (B) for 3 h prior to stimulation with 800
ng of purified Stx1/ml. Twelve hours later, culture supernatants were collected
and TNF bioactivity was determined by lysis of actinomycin D-treated L929 cells.
Results shown are mean levels of TNF bioactivity (picograms/milliliter) 6 stan-
dard errors of the means for three independent experiments.
FIG. 3. Effect of Stx1 on PKC activation in THP-1 cells. PMA-differentiated
THP-1 cells were treated with purified Stx1 (800 ng/ml) for 3 h or PMA for 1 h.
Some cells were pretreated with the PKC inhibitor H-7 (50 mM) or K252a (500
nM) or the PKA inhibitor H-89 (1000 nM) for 3 h prior to stimulation with 800
ng of purified Stx1/ml. PKC activation was assessed by measuring the transfer of
32P to a synthetic PKC substrate. Data shown are means 6 standard errors of the
means for three independent experiments.











kinase inhibitor genistein, which reduced levels of phosphory-
lation to levels detected in untreated controls (Fig. 5, compare
lanes 1 and 4). This finding led us to assess the role of protein
tyrosine kinases in Stx-mediated TNF-a production. We
treated monocytes with the tyrosine kinase inhibitor genistein
prior to Stx1 exposure and monitored TNF-a secretion. Pre-
treatment of THP-1 cells with genistein for 2 h inhibited Stx1-
and LPS-mediated TNF-a production (Fig. 6). Exposure of the
cells to the carrier solvent DMSO or to genistein plus DMSO
did not induce TNF-a production. Thus, Stx1 treatment of
monocytic cells induced tyrosine phosphorylation, the inhibi-
tion of which was associated with the loss of cytokine expres-
sion.
DISCUSSION
Data presented in this study and elsewhere (26, 43) suggest
that sublethal concentrations of Stxs induce TNF-a and IL-1b
expression by human monocytes and monocytic cell lines. We
demonstrate that cytokine production in response to Stx treat-
ment correlates with toxin A subunit enzymatic activity, as
mutants with markedly reduced N-glycosidase activity, but re-
taining the ability to form AB5 holotoxins and bind to the cells
via Gb3 or Gb4 receptors, fail to elicit TNF-a production.
Furthermore, treatment of monocytes with ricin, a toxin pos-
sessing an identical mechanism of action as Stx A subunits,
elicits TNF-a production. Binding of Gb3 by Stx1 B subunits or
antibody against Gb3 was not sufficient to trigger cytokine
production.
The precise mechanisms by which Stxs trigger increased
cytokine synthesis and secretion by monocytes is unknown. A
number of well-characterized transmembrane signaling path-
ways are triggered by growth factor-growth factor receptor
interactions (31). The lipid A component of LPS has been
shown to bind to a number of monocyte/macrophage membrane
proteins, including CD14, b2 leukocyte integrins (CD11a,b,c/
CD18), and the scavenger receptor (reviewed in reference 7).
Following LPS binding to membrane receptors, transmem-
brane signaling may be initiated by toll-like receptors, a series
of signal transfer proteins. In contrast to growth factors or
LPS, Stxs and ricin do not appear to stimulate host cell signal-
ing cascades solely through the simple interaction of toxins
with membrane receptors. Rather, it appears that wild-type
toxins must enter cells, undergo retrograde intracellular rout-
ing, and initiate cell signaling cascades from within the cell. A
likely starting point for cell signal initiation is the ribosome
(15), and studies are under way to link Stx-mediated ribosome
inactivation with cytokine production by monocytic cells.
Stx-mediated cytokine induction by monocytes was depen-
dent on cell differentiation and toxin dose. Treatment of toxin-
FIG. 4. Effect of PKC inhibitors on Stx1-mediated TNF-a mRNA synthesis
by THP-1 cells. PMA-differentiated THP-1 cells were treated with purified Stx1
with or without protein kinase inhibitors as outlined in the legend to Fig. 3. Total
RNA was isolated from the cells, and TNF-a mRNA was detected by Northern
blot analysis. Ratios shown are the means 6 standard errors of the means for
three separate experiments.
FIG. 5. Stx1-induced phosphorylation of tyrosine residues in THP-1 cells.
Differentiated THP-1 cells were preincubated with 100 mM genistein or vehicle
for 2 h followed by exposure to Stx1 (400 ng/ml) with or without the kinase
inhibitor. Cells were also treated with the inhibitor or DMSO vehicle alone. Cells
were lysed, and extracts were cleared by centrifugation. Equal amounts of pro-
tein were separated by SDS–12% PAGE and analyzed by Western blotting using
an anti-phosphotyrosine monoclonal antibody, 4G10, as described in Materials
and Methods. Closed arrows indicate phosphoproteins induced by Stx1 treat-
ment that are sensitive to genistein. The open arrow indicates a phosphoprotein
band of decreased intensity following Stx1 treatment that appears restored fol-
lowing inhibitor treatment.











sensitive undifferentiated THP-1 cells with Stxs (400 ng/ml)
resulted in cell death without cytokine release (26). In contrast,
cytokine production manifested in differentiated THP-1 cells
following treatment with an identical dose of Stx1 which was
sublethal and did not drastically alter protein synthesis. The
cytokine induction ability of sublethal doses of Stxs may not be
limited to proinflammatory cytokine production by myeloid
cells. Recently, it was shown that human intestinal epithelial
cells, although relatively sensitive to Stxs, secreted the chemo-
kine IL-8 when treated with doses of purified Stxs that medi-
ated only ;10% of the cell killing (39, 45). Interestingly, IL-8
production by the human colonic epithelial cell line Caco2 also
required A subunit activity (45). These data suggest that cyto-
kine and chemokine induction within localized tissues may
occur in the presence of concentrations of Stxs that are suble-
thal for cells in vitro.
To determine signaling components involved in Stx-medi-
ated TNF-a production, we examined the role of PKC, PKA,
and protein tyrosine kinases in induction. The PKC family of
serine/threonine kinases contains at least 12 isoforms that are
involved in signal transduction, regulation of gene expression,
and myeloid differentiation (21). The PKC family is subdivided
into three groups: (i) the conventional PKC group containing
isoforms requiring both Ca21 and diacylglycerol (DAG), phos-
phoserine, or phorbol esters for activation, (ii) the Ca21-inde-
pendent PKC group, requiring only DAG, phosphoserine, or
phorbol esters for activation, and (iii) the atypical PKC iso-
forms, which require neither Ca21 nor lipids for activation and
are insensitive to phorbol esters. Various PKC isoforms have
been implicated in LPS-mediated signaling, but their role in
induction of TNF-a remains controversial (25, 32, 33). Shapira
et al. (33) showed that LPS-stimulated human monocyte pro-
duction of TNF-a and IL-1 was blocked by both tyrosine kinase
and PKC inhibitors. However, a DAG-dependent kinase in-
hibitor did not affect LPS-induced TNF-a production, suggest-
ing that atypical PKC isoforms may be involved in LPS signal-
ing. Herrera-Velit et al. (13) showed that LPS treatment of
human monocytes resulted in the selective activation of the
atypical PKC-z isoform. Atypical PKC isoforms may, in turn,
be linked to activation of downstream kinases, such as the
extracellular signal-regulated kinase cascade, involved in LPS-
mediated signaling (9, 27, 44). The results presented here sug-
gest that PKC activation in differentiated THP-1 cells is essen-
tial in Stx-mediated signaling for TNF-a production. The
position of PKC in the signaling pathway and the identity of
the PKC isoform(s) involved in Stx signaling remain to be
determined.
Using the tyrosine kinase inhibitor genistein, TNF-a produc-
tion by THP-1 cells stimulated by Stx1 was decreased. Thus,
protein tyrosine kinases are also involved in Stx-mediated sig-
naling. Several possible candidate kinase pathways that contain
tyrosine kinase activity have been characterized in LPS-treated
monocytes, including the extracellular signal-regulated kinase,
c-Jun N-terminal kinase, and p38 mitogen-activated protein
kinase cascades (5, 12, 35, 44). It will be necessary to screen
specific components of these pathways to establish their role in
Stx signaling since the parallels between LPS- and Stx-induced
signaling are currently unknown.
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